G
Genetic Archaeology
GENETIC ARCHAEOLOGY // PROFILE

CYP2C19

Cytochrome P450 Family 2 Subfamily C Member 19

CHR 10
10q23.33

Overview

The CYP2C19 gene encodes one of the most clinically actionable enzymes in the human liver from the cytochrome P450 superfamily. It processes roughly 10 to 15 percent of all commonly prescribed medications, including the antiplatelet drug clopidogrel, proton pump inhibitors (omeprazole, pantoprazole), selective serotonin reuptake inhibitors (citalopram, escitalopram, sertraline), and antifungals like voriconazole.

Depending on inherited star alleles, individuals range from Poor Metabolizers to Ultrarapid Metabolizers—a cornerstone of modern clinical pharmacogenetics.

📍 Position
10q23.33 (Chromosome 10)
🏷️ Category
Detoxification & Pharmacogenetics
🧪 Function
Phase I Hepatic Enzyme (Oxidation)
📊 Influence
Drug activation & hepatic clearance

Function of CYP2C19

In Phase I hepatic metabolism, CYP2C19 either breaks down active drugs so the body can clear them safely, or converts inactive prodrugs (such as clopidogrel) into their active therapeutic form.

Key Aspects:

🐌 Loss-of-Function (*2 / rs4244285)

Two non-functional copies prevent clopidogrel activation after coronary stenting, increasing thrombotic risk, while elevating blood levels of SSRIs like citalopram.

⚡ Ultrarapid (*17 / rs12248560)

Heightened transcription clears acid-suppressing PPIs or antidepressants so rapidly that standard doses may fail to achieve therapeutic blood concentrations.

💡 Clinical Actionability: CPIC (Clinical Pharmacogenetics Implementation Consortium) guidelines recommend alternative antiplatelets like prasugrel or ticagrelor after PCI/stents for CYP2C19 poor and intermediate metabolizers.

🧬 Genetic Variants (SNPs)

Two hallmark polymorphisms determine most European and global CYP2C19 metabolizer phenotypes:

rs4244285
10:94781859
Normal (*1)

G
/
Loss (*2)

A
CYP2C19*2 (c.681G>A)
Creates an aberrant splice site resulting in non-functional protein; severely reduces clopidogrel activation and slows SSRI breakdown.
*2 allele frequency:
~15% (Europe), ~30% (East Asia)
rs12248560
10:94761900
Reference

C
/
Gain (*17)

T
CYP2C19*17 (c.-806C>T)
Increases promoter binding and enzyme output, accelerating clearance of PPIs, escitalopram, and voriconazole.
*17 allele frequency:
~21% (Europe)

Practical Significance

✅ Strategies & Guidance

  • Pre-Treatment Cardiology Review: Share known *2/*2 or *1/*2 status before starting clopidogrel post-stent or stroke.
  • Targeted SSRI Dosing: Physicians may adjust citalopram, escitalopram, or sertraline doses or choose non-CYP2C19 options.
  • Medication Interaction Awareness: Inhibitors such as omeprazole or fluvoxamine can phenoconvert a normal metabolizer into a slower state.

⚠️ Clinical Notes & Risks

  • Reduced Antiplatelet Protection: Inadequate clopidogrel bioactivation raises cardiovascular event risk.
  • SSRI Side Effects (PM): Higher risk of QT prolongation or nausea on standard citalopram doses.
  • Treatment Failure (UM): Underdosing in severe reflux or H. pylori eradication regimens with PPIs.
🩺 Medical Disclaimer: Genetic test results for CYP2C19 (Cytochrome P450 Family 2 Subfamily C Member 19) should always be interpreted alongside laboratory biomarkers, medications, and qualified medical or genetic counseling.

📚 Data Sources

  • OMIM: #124020 (Cytochrome P450, Subfamily IIC, Polypeptide 19)
  • dbSNP: rs4244285 (*2), rs12248560 (*17)
  • CPIC Guideline: CYP2C19 Genotype and Clopidogrel / SSRI Therapy
  • PharmGKB: Clinical Annotations Level 1A for CYP2C19

Last Update: November 2026

Related Research Guides for CYP2C19

Related Genes in Detoxification